PDF(Pubmed)
Abstract：
UNASSIGNED: The predictive role of modified Glasgow prognostic score (mGPS) for long-term survival in several types of cancers has been well manifested. We supposed that preoperative mGPS might also be associated with long-term survival of operated non-small cell lung cancer (NSCLC) patients. The aim of this meta-analysis was to identify the prognostic value of preoperative mGPS in surgical NSCLC patients.
UNASSIGNED: The PubMed, Web of Science, EMBASE and CNKI databases were searched for relevant studies up to November 7, 2022. The primary and secondary outcomes were overall survival (OS) and disease-free survival (DFS), respectively. The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined.
UNASSIGNED: A total of 3,803 patients from 11 studies were enrolled and analyzed. The combined results demonstrated elevated preoperative mGPS was significantly related to poorer OS (HR = 2.11, 95% CI: 1.83-2.44, P < 0.001) and DFS (HR = 1.70, 95% CI: 1.42-2.03, P < 0.001). Subgroup analysis for the OS further identified the predictive role of elevated preoperative mGPS for worse OS in NSCLC.
UNASSIGNED: Preoperative mGPS was significantly associated with prognosis in NSCLC and patients with elevated preoperative mGPS experienced poorer long-term survival.
UNASSIGNED: The PubMed, Web of Science, EMBASE and CNKI databases were searched for relevant studies up to November 7, 2022. The primary and secondary outcomes were overall survival (OS) and disease-free survival (DFS), respectively. The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined.
UNASSIGNED: A total of 3,803 patients from 11 studies were enrolled and analyzed. The combined results demonstrated elevated preoperative mGPS was significantly related to poorer OS (HR = 2.11, 95% CI: 1.83-2.44, P < 0.001) and DFS (HR = 1.70, 95% CI: 1.42-2.03, P < 0.001). Subgroup analysis for the OS further identified the predictive role of elevated preoperative mGPS for worse OS in NSCLC.
UNASSIGNED: Preoperative mGPS was significantly associated with prognosis in NSCLC and patients with elevated preoperative mGPS experienced poorer long-term survival.
摘要：
UASSIGNED：改良的格拉斯哥预后评分（mGPS）对几种癌症的长期生存的预测作用已得到很好的体现。我们认为术前mGPS也可能与手术的非小细胞肺癌（NSCLC）患者的长期生存有关。这项荟萃分析的目的是确定术前mGPS在手术NSCLC患者中的预后价值。
未经授权：PubMed，WebofScience,截至2022年11月7日，在EMBASE和CNKI数据库中搜索相关研究。主要和次要结局是总生存期（OS）和无病生存期（DFS），分别。将风险比(HR)和95%置信区间(CIs)组合。
UNASSIGNED：共纳入11项研究的3,803例患者并进行分析。合并结果显示，术前mGPS升高与OS较差（HR=2.11，95％CI：1.83-2.44，P<0.001）和DFS（HR=1.70，95％CI：1.42-2.03，P<0.001）显着相关。OS的亚组分析进一步确定了术前mGPS升高对NSCLC不良OS的预测作用。
UNASSIGNED：术前mGPS与NSCLC的预后显著相关，术前mGPS升高的患者的长期生存率较差。
未经授权：PubMed，WebofScience,截至2022年11月7日，在EMBASE和CNKI数据库中搜索相关研究。主要和次要结局是总生存期（OS）和无病生存期（DFS），分别。将风险比(HR)和95%置信区间(CIs)组合。
UNASSIGNED：共纳入11项研究的3,803例患者并进行分析。合并结果显示，术前mGPS升高与OS较差（HR=2.11，95％CI：1.83-2.44，P<0.001）和DFS（HR=1.70，95％CI：1.42-2.03，P<0.001）显着相关。OS的亚组分析进一步确定了术前mGPS升高对NSCLC不良OS的预测作用。
UNASSIGNED：术前mGPS与NSCLC的预后显著相关，术前mGPS升高的患者的长期生存率较差。
